Anteris Technologies Global Corp (AVR)

NASD · Healthcare · Medical Devices · USA

Anteris Technologies Global Corp is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

Anteris Technologies Global Corp develops the DurAVR THV System, a transcatheter aortic valve replacement device for treating aortic stenosis. The system combines a single-piece biomimetic valve manufactured with proprietary ADAPT tissue technology and a balloon-expandable delivery mechanism. The company is conducting the PARADIGM Trial to evaluate the device's safety and efficacy.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Anteris Technologies Global Corp stock.

Our verdict on AVR

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover two fiscal years and projecting growth needs four in a row.

ETFs with the most weight in AVR

16 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than AVR in Medical Devices

61 more in this industry show a wider margin of safety.

Is AVR undervalued or overvalued?

We do not publish a verdict on AVR yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of AVR?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.